{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:47Z","timestamp":1786984427247,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019949","name":"FUJIFILM Toyama Chemical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.antiviral.2022.105489","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T11:01:43Z","timestamp":1670670103000},"page":"105489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Implications of the antiviral drug favipiravir on rabies immunoglobulin for post-exposure prophylaxis of rabies in mice model with category III-like exposures"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-0466","authenticated-orcid":false,"given":"Kazunori","family":"Kimitsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakirul","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kaimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Yahiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-4554","authenticated-orcid":false,"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz P.","family":"Quiambao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-759X","authenticated-orcid":false,"given":"Phatthamon","family":"Virojanapirom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiravat","family":"Hemachudha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishizono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105489_bib1","first-page":"407","article-title":"Effects of homologous or heterologous antiserum on neutralizing-antibody response to rabies vaccine","volume":"39","author":"Archer","year":"1968","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.antiviral.2022.105489_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib3","first-page":"1192","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.antiviral.2022.105489_bib4","article-title":"In vivo efficacy of SYN023, an anti-rabies monoclonal antibody cocktail, in post-exposure prophylaxis animal models","volume":"5","author":"Chao","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib5","series-title":"Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, medRxiv","author":"Chen","year":"2020"},{"key":"10.1016\/j.antiviral.2022.105489_bib6","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/j.vaccine.2010.08.034","article-title":"Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis","volume":"28","author":"Fang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2022.105489_bib7","series-title":"Rabies","year":"2020"},{"key":"10.1016\/j.antiviral.2022.105489_bib8","doi-asserted-by":"crossref","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.antiviral.2022.105489_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105489_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004348","article-title":"Rabies virus hijacks and accelerates the p75NTR retrograde axonal transport machinery","volume":"10","author":"Gluska","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2022.105489_bib11","first-page":"459","article-title":"Demographics of animal bite victims & management practices in a tertiary care institute in Mumbai, Maharashtra, India","volume":"139","author":"Gogtay","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.antiviral.2022.105489_bib12","article-title":"Global alliance for rabies control partners for rabies prevention","volume":"9","author":"Hampson","year":"2015"},{"key":"10.1016\/j.antiviral.2022.105489_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1474-4422(13)70038-3","article-title":"Human rabies: neuropathogenesis, diagnosis, and management","volume":"12","author":"Hemachudha","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.antiviral.2022.105489_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac046","article-title":"A country classification system to inform rabies prevention guidelines and regulations","author":"Henry","year":"2022","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.antiviral.2022.105489_bib15","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1099\/jgv.0.000950","article-title":"Near-infrared fluorescent protein iRFP720 is optimal for in vivo fluorescence imaging of rabies virus infection","volume":"98","author":"Isomura","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2022.105489_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/POR.S364066","article-title":"Real-world experience with favipiravir for the treatment of mild-to-moderate COVID-19 in India","volume":"13","author":"Joshi","year":"2022","journal-title":"Pragmatic Observational Res."},{"key":"10.1016\/j.antiviral.2022.105489_bib18","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1086\/344954","article-title":"Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin","volume":"35","author":"Khawplod","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib19","doi-asserted-by":"crossref","DOI":"10.1292\/jvms.17-0028","article-title":"Pathological lesions in the central nervous system and peripheral tissues of ddY mice with street rabies virus (1088 strain)","volume":"79","author":"Kimitsuki","year":"2017","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.antiviral.2022.105489_bib20","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1016\/j.vaccine.2012.04.003","article-title":"Evaluation of an improved rapid neutralizing antibody detection test (RAPINA) for qualitative and semiquantitative detection of rabies neutralizing antibody in humans and dogs","volume":"30","author":"Nishizono","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2022.105489_bib21","first-page":"1","article-title":"The cellular immune response to rabies vaccination: a systematic review","volume":"7","author":"Overduin","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.antiviral.2022.105489_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2022.105489_bib23","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"48","author":"Smith","year":"1973","journal-title":"Bull. World Health Organ."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2022.105489_bib24","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: a review of the current status of the clinical development pipeline","volume":"37","author":"Sparrow","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2022.105489_bib25","series-title":"Overview of Rabies Post-exposure Prophylaxis Access, Procurement and Distribution in Selected Countries in Asia and Africa, 2017\u20132018. Vaccine","author":"Sreenivasan","year":"2019"},{"key":"10.1016\/j.antiviral.2022.105489_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/infdis\/jiw174","article-title":"T-705 as a potential therapeutic agent for rabies","volume":"214","author":"Virojanapirom","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tmaid.2011.12.005","article-title":"Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure","volume":"10","author":"Warrell","year":"2012","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/archneur.64.9.1355-a","article-title":"Humoral immune responses after rabies infection","volume":"64","author":"Watson","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.antiviral.2022.105489_bib29","unstructured":"WHO, 2018. WHO Expert Consultation on rabies: Third report [WWW Document]. World Health Organisation."},{"key":"10.1016\/j.antiviral.2022.105489_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/324628","article-title":"Postexposure treatment of rabies infection: can it be done without immunoglobulin?","volume":"34","author":"Wilde","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105489_bib31","author":"World Health Organisation (WHO)"},{"key":"10.1016\/j.antiviral.2022.105489_bib32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-0716-2453-1_28","article-title":"In vivo bioluminescent imaging of rabies virus infection and evaluation of antiviral drug","volume":"2524","author":"Yamada","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2022.105489_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104641","article-title":"Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis","volume":"172","author":"Yamada","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105489_bib34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"JID (J. Infect. Dis.)"},{"key":"10.1016\/j.antiviral.2022.105489_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2022.102267","article-title":"Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models","volume":"46","author":"Zhai","year":"2022","journal-title":"Trav. Med. Infect. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:37:04Z","timestamp":1759063024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222002583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["S0166354222002583"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105489","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of the antiviral drug favipiravir on rabies immunoglobulin for post-exposure prophylaxis of rabies in mice model with category III-like exposures","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105489"}}